-
Study aim
-
Comparison of the efficacy, safety, tolerability and satisfaction of SVF injection in the treatment of androgenetic alopecia
-
Design
-
This phase 1 study is performed on 24 patients with hair loss. In each session, one side is treated with SVF (intervention) injection and the other side is treated with normal saline (control) injection. All patients before the treatment and 2 months after the second visit and photos are taken by digital camera and tricoscan. To determine the extent of improvement and compare the two groups, at the end of the study, photos of patients are examined by two neutral dermatologists. Patients' satisfaction and tolerance are also recorded and the results are compared.
-
Settings and conduct
-
This project is performed in the Skin and Stem Cell Research Center of Tehran University of Medical Sciences and without informing the patients, one side receives SVF as an injection and the other group receives normal saline.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Men and women with hereditary hormonal hair loss, age 18 years and older and less than 50 years, Hamilton score 2 to 5 in men and Ludwig score 1 to 3 in women, complete patient consent to participate in the project. Exclusion criteria: platelet disorders, thrombocytopenia, patients receiving anticoagulants, patients with malignancy, receiving chemotherapy in the last 5 years, patients with sepsis, smoking, pregnancy, ulcers or active infections at the treatment site, not receiving any topical medication Or systemic medication in the last 3 months, women with hyperprolactinemia, women with hormonal disorders or polycystic ovaries.
-
Intervention groups
-
In each session, one side is treated with SVF (intervention) injection and the other side is treated with normal saline (control) injection.
-
Main outcome variables
-
The amount of hair loss; side effects; patient's satisfaction; tolerability